# 2025-16275: SOFDRA's Patent Gets FDA-Approved Time Extension Boost

2025-16275, Determination of Regulatory Review Period for Purposes of Patent Extension; SOFDRA, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-08-26 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-16275
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-16275
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; SOFDRA
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 41573
- Published: 2025-08-26
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

SOFDRA's Patent Gets FDA-Approved Time Extension Boost

## Summary

The FDA has officially set the review period for SOFDRA, a human drug product, so its patent can be extended. This helps the drug maker get extra time to protect their invention after the long approval process. If you’re involved in drug patents or development, this means important deadlines and opportunities to keep an invention exclusive and valuable.

## Abstract

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SOFDRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claim that human drug product.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-16275 on federalregister.gov](https://www.federalregister.gov/documents/2025/08/26/2025-16275/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sofdra)
- [2025-16275 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-08-26/pdf/2025-16275.pdf)

## Related
- [Previous: 2025-16274, Determination of Regulatory Review Period for Purposes of Patent Extension; PIA…](https://policyrisk.com/federal-register/2025-16274)
- [Next: 2025-16276, Notice of Scope Ruling Applications Filed in Antidumping and Countervailing Dut…](https://policyrisk.com/federal-register/2025-16276)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-16275 (as of 2026-06-08).
